IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection
Martin Lagging, Ana I. Romero, Johan Westin, Gunnar Norkrans, Amar P. Dhillon, Jean‐Michel Pawlotsky, Stefan Zeuzem, Michael von Wagner, Francesco Negro, Solko W. Schalm, Bart L. Haagmans, Carlo Ferrari, Gabriele Missale, Avidan U. Neumann, Elke Verheij‐Hart, Kristoffer Hellstrand, DITTO‐HCV Study Group – 28 November 2006 – Plasma from 173 patients with HCV genotype 1 infection was analyzed for IP‐10 levels prior to treatment with pegylated interferon‐α‐2a and ribavirin.